Skip to Main Content

Paper Details

Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.
PLoS One
16
2018
ATC, ATC cell lines, Anaplastic thyroid cancer, JAK2, Lestaurtinib, anaplastic thyroid cancer, chick, human, malignancy, single cells
Animals, Antineoplastic Agents, Apoptosis, Carbazoles, Cell Cycle, Cell Line, Tumor, Cell Movement, Cell Proliferation, Chick Embryo, Dose-Response Relationship, Drug, Furans, Humans, Janus Kinase 2, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Xenograft Model Antitumor Assays
Author NameAffiliation
Nicole PintoWestern University
Nicole PintoWestern University
Stephenie D ProkopecOntario Institute for Cancer Research
Frederick S VizeacoumarUniversity of Saskatchewan
Karlee SearleWestern University
Matthew R LowerisonWestern University
Kara M RuicciWestern University
John YooWestern University
Kevin FungWestern University
Stephanie Danielle MacNeilWestern University
James C LacefieldWestern University
Hon S LeongMayo Clinic
Joe S MymrykWestern University
Joe S MymrykWestern University
John W BarrettWestern University
John W BarrettWestern University
Alessandro DattiLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital
Alessandro DattiUniversity of Perugia
Paul C BoutrosOntario Institute for Cancer Research
Paul C BoutrosUniversity of Toronto
Paul C BoutrosUniversity of Toronto
Anthony C NicholsWestern University
Anthony C NicholsWestern University
  • 1 - 23

Datasets

Release 1.2